Drug Trial Radar · NCT06533657
Unique Treatment of Oncology Pain in Advanced Cancer
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11
Actual
Start
Jun 12, 2025
Primary completion
Apr 15, 2026
Study completion Apr 15, 2026
Sponsor
- Lead sponsor
- ZYUS Life Sciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be a proof-of-concept, single arm study with a maximum of 20 patients to evaluate preliminary analgesic efficacy and safety of Trichomylin® in patients with advanced cancer (male and female) who suffer from moderate to severe chronic pain and who are taking a stable dose of long-acting opioid therapy for at least 1 week prior to screening.
Conditions
- Cancer Pain
Interventions
Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)Drug
Cancer patients meeting eligibility criteria will receive Trichomylin® and self-titrate to effective dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants That Reach the Stable Dose during Dose TitrationTime frame: Baseline (i.e. Day 1 Dose Titration) and Stable Dose Day 1, up to 14 days
- Change in Average Pain Scores from Baseline to Investigational Product DiscontinuationTime frame: Baseline and Investigational Product Discontinuation, up to 23 days
- Proportion of Responders to Average Pain from Baseline to Investigational Product DiscontinuationTime frame: Baseline and Investigational Product Discontinuation, up to 23 days
- Number of Participants That Reach the Stable Dose during Dose Titration and Respond to Average Pain from Baseline to Investigational Product DiscontinuationTime frame: Baseline and Investigational Product Discontinuation, up to 23 days
- Change in Average Pain from Baseline to End of the TitrationTime frame: Baseline and End of Dose Titration, up to 14 days
- Change in Pain Interference from Baseline to End of the TitrationTime frame: Baseline and End of DoseTitration, up to 14 days
- Change in Pain Interference from Baseline to Investigational Product DiscontinuationTime frame: Baseline and Investigational Product Discontinuation, up to 23 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
CancerCare Manitoba
Winnipeg, Manitoba, Canada
Centre hospitalier de l'Université de Montréal
Montreal, Quebec, Canada
The Research Institute of the McGill University Health Centre
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.